Eli Lilly settles insulin suit for $13.5 million, agrees to keep price cap

The class-action lawsuit filed six years ago against drugmaker Eli Lilly alleging systematic overpricing of insulin has ended with the company agreeing to pay a $13.5 million settlement and to continue its cap on users’ out-of-pocket costs for four years.